Mes: diciembre 2020

NEW YORK, Dec. 28, 2020 /PRNewswire/ — Ideanomics (NASDAQ: IDEX) («Ideanomics» or the «Company») announces that its Mobile Energy Global («MEG») and its contracting entity Qingdao Chengyang Medici have signed an agreement with Meihao Chuxing, a joint venture between BYD and Didi, to purchase an initial 2,000 units of model BYD D1. The ride-hailing vehicles are intended for deployment in multiple cities within China, with deliveries expected to begin in H1 2021.

«The D1 is a very thoughtfully designed ride-hailing EV and is a culmination of the latest design and technology to bring drivers and their customers an enjoyable travel experience. We are very pleased to work with Meihao Chuxing and BYD to promote the sales of the D1,» said Alf Poor, Ideanomics CEO. «Supported by a viable government subsidy program, the proliferation of EVs in China is a testament to the value that public and private partnerships can bring to large scale global challenges. We look forward to developing these types of partnerships and the rollout of more innovative vehicles like the D1 to our taxi and ride-hailing customers.» 

Meihao Chuxing (Hangzhou) Automobile Technology Co., Ltd. was established in 2019, though a 65/35 joint venture between BYD and Didi with BYD having controlling interest. Launched in November 2020, model BYD D1 was jointly developed by BYD and Didi as the world’s first custom-built, all electric car for ride-hailing. The vehicles feature L2 Assisted Driving system, are linked with a fleet management system that helps large fleet operators track and optimize operational status, real-time energy management, as well as a myriad of other safety and comfort features. BYD D1 is equipped with its latest Blade Battery (LFP chemistry) with a range of 418 km (260 miles) and can reach top speeds of 130 km/h (81 mph). Didi Chuxing is deploying and promoting the ride-hailing service in a number of Chinese cities. Passengers can order the customized ride-sharing service via the Didi app.

Please refer to the company’s 8-k filings for further material details of the agreement

About BYD
BYD Company Ltd. is one of China’s largest privately owned enterprises. Since its inception in 1995, the company quickly developed solid expertise in rechargeable batteries and became a relentless advocate of sustainable development, successfully expanding its renewable energy solutions globally with operations in over 50 countries and regions. Its creation of a Zero Emissions Energy Ecosystem – comprising affordable solar power generation, reliable energy storage, and cutting-edge electrified transportation – has made it an industry leader in the energy and transportation sectors. BYD is listed on the Hong Kong and Shenzhen Stock Exchanges. More information on the company can be found at www.byd.com.

About Ideanomics
Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. Our Mobile Energy Global (MEG) division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under our innovative sales to financing to charging (S2F2C) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, MEG and Ideanomics Capital provide our global customers and partners with leading technologies and services designed to improve transparency, efficiency, and accountability, and our shareholders with the opportunity to participate in high-potential, growth industries.

The company is headquartered in New York, NY, with offices in Beijing, Hangzhou, and Qingdao, and operations in the U.S., China, Ukraine, and Malaysia.

Safe Harbor Statement
This press release contains certain statements that may include «forward looking statements». All statements other than statements of historical fact included herein are «forward-looking statements.» These forward-looking statements are often identified by the use of forward-looking terminology such as «believes,» «expects» or similar expressions, involve known and unknown risks and uncertainties, and include statements regarding our intention to transition our business model to become a next-generation financial technology company, our business strategy and planned product offerings, our intention to phase out our oil trading and consumer electronics businesses, and potential future financial results. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of risks and uncertainties, such as risks related to: our ability to continue as a going concern; our ability to raise additional financing to meet our business requirements; the transformation of our business model; fluctuations in our operating results; strain to our personnel management, financial systems and other resources as we grow our business; our ability to attract and retain key employees and senior management; competitive pressure; our international operations; and other risks and uncertainties disclosed under the sections entitled «Risk Factors» and «Management’s Discussion and Analysis of Financial Condition and Results of Operations» in our most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, and similar disclosures in subsequent reports filed with the SEC, which are available on the SEC website at www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations and Media Contact

Ideanomics, Inc.
Tony Sklar, SVP of Investor Relations
1441 Broadway, Suite 5116 New York, NY 10018
ir@ideanomics.com

Valerie Christopherson / Lora Wilson
Global Results Communications (GRC)
+1 949 306 6476
valeriec@globalresultspr.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/meg-announces-purchase-agreement-for-2-000-units-of-d1–byds-custom-electric-ride-hailing-vehicle-301198604.html

SOURCE Ideanomics

WASHINGTON, Dec. 27, 2020 /PRNewswire/ — The American Association of Kidney Patients (AAKP), the largest and oldest kidney patient organization in the United States, released the following statement upon President Donald J. Trump’s signing of bipartisan, Congressionally authorized immunosuppressive drug coverage provisions for kidney transplant patients. The provisions were included in Congressional actions related to the COVID-19 pandemic relief package and $1.4 trillion omnibus spending bill. AAKP patient volunteers used the organization’s sophisticated communications systems to drive Congressional action and mobilize the most comprehensive national grassroots campaign in its 50-year history, the effort included, coordinated local virtual kidney patient networks, text messages, emails, and multiple social media platforms. In 2018, AAKP launched the first kidney patient voter registration campaign in the kidney community, «Kidney Voters,» which expanded exponentially in 2020 and has provided unique data insights to better target kidney patient voices in national policy debates and Congressional deliberations. AAKP will engage and educate over 500,000 «Kidney Voters» by 2024.

The new coverage provisions end the current, arbitrary 36-month limit on transplant drug coverage for kidney transplant recipients–a massive policy reversal that kidney patient advocates, transplant professionals, and allied members of the kidney community have fought to change for two decades. Kidney transplant patients must take a lifetime course of immunosuppressive drugs to keep their transplanted kidneys working and to prevent organ rejection. Interruptions to drug coverage have serious impacts on transplant recipients; can lead to organ rejection; and a return to high cost, high mortality dialysis–a comparatively less ideal treatment for kidney failure. The Congressional Budget Office reports that the policy change will positively impact hundreds of kidney transplant patients every year and save taxpayers hundreds of millions of dollars over the next ten years.

AAKP STATEMENT

«The American Association of Kidney Patients extends our appreciation to President Trump for signing pandemic relief for Americans in desperate need and for extending immunosuppressive drug coverage to kidney transplant patients. In 2019, President Trump and HHS Secretary Alex Azar, consistent with insights shared by kidney patients and the medical allies with whom they met, initiated a bold reform vision for the outdated, status quo kidney care system through the Executive Order on Advancing American Kidney Health. We are pleased Congress also listened to kidney patients and their medical allies and took bipartisan action to support the reform vision. The extension of immunosuppressive drug coverage and elimination of the current, arbitrary 36-month limit removes a long-standing barrier to increased kidney donation, kidney transplantation, and patient care choice. The signing of this bill marks a historic milestone for the first year of the AAKP initiated and led Decade of the Kidney™ and we will closely monitor implementation. In memory of all patient advocates who worked for this policy change, and whose lives ended before they could witness this victory, AAKP will expand our capacities to organize, train, and mobilize kidney patients to achieve even greater transformations to status quo kidney care in the years ahead.»

In 2019, upon the signing of President Trump’s Executive Order on Advancing American Kidney Health, AAKP launched The Decade of the Kidney™, a strategic effort to organize kidney patient consumers nationally and globally to drive policies to support greater patient care choice, accelerate timely access to treatment options including preemptive kidney transplants, drive innovations including artificial implantable and wearable kidneys, expand kidney precision medicine and research, and prevent kidney injury and disease. AAKP has been a staunch defender of kidney patient care choice and defines quality kidney care as a treatment that best aligns with patient aspirations, including the ability to work full-time or part- time and have a career, to start a family, own a home, and retire securely. AAKP and its allies have worked against corporate dialysis industry efforts in Congress to deny kidney patient consumers their right to care choice and access to treatment innovations and spearheaded kidney patient efforts that helped defeat the controversial Dialysis Patients Demonstration Act. AAKP is currently organizing kidney patients nationwide to defeat another dialysis industry backed bill that limits kidney patient care choice, the «BETTER» Kidney Care Act.

In a statement (read announcement) issued December 21, 2020, U.S. Senate passage of immunosuppressive drug coverage, AAKP thanked Senate Majority Leader Mitch McConnell (R-KY), Senate Minority Leader Chuck Schumer (D-NY), Senator Bill Cassidy (R-LA), Senator Dick Durbin (D-IL), and Senator Joe Manchin (D-WV) and their Senate colleagues for listening to the voices of kidney patients and reversing the current, arbitrary 36-month limit on transplant drug coverage. Similarly, AAKP issued a statement (read announcement) on December 8, 2020, after the U.S. House of Representatives passed similar language. AAKP thanked Speaker Nancy Pelosi (D-CA), Minority Leader Kevin McCarthy (R- CA), Representatives Ron Kind (D-WI), Michael Burgess (R-TX), Jimmy Panetta (D-CA), Jason Smith (R-MO), and all other Congressional Members for respect for kidney patient insights on the need for immunosuppressive drug coverage. AAKP leaders have also recognized the role of U.S. Secretary of Health and Human Services Alex Azar, Comptroller General of the United States Gene Dodaro, and Congressional Budget Office Directors Phillip Swagel, predecessor Keith Hall, and their staffs for respecting the unique insights and life experiences of patients who have fought to maintain their transplants amidst the loss of immunosuppressive drug coverage.

In November of 2020, over 25 AAKP kidney advocates were recognized with the President’s Volunteer Service Award (PVSA) for their ongoing advocacy for kidney transplants and response to the COVID-19 pandemic (read announcement). AAKP patient volunteers provide an independent patient view on kidney issues through sophisticated virtual platforms, international patient group partnerships, clinical journal editorials, television, radio, social media, and a growing Patient Ambassador Initiative. At the start of the COVID-19 pandemic, AAKP transitioned all 2020 events to free virtual access, prioritized COVID-19 topics, and leveraged tactics to engage a wider audience. In the past eight months, AAKP has broadcasted expert COVID-19 insights through one global and two national virtual events, a dozen webinars, and launched advocacy campaigns to highlight disparities in minority and kidney patient representation in COVID-19 clinical trials and vaccine distribution protocols. Viewership for 2020 AAKP programs now exceeds 80,000 people across 70 countries and is growing rapidly. International and national program faculty have included 90 medical practitioners and researchers, and 60 patient experts. The AAKP Global Summit on Kidney Innovations, conducted in partnership with The George Washington University School of Medicine and Health Sciences, alone reached over 20,000 patients and professionals worldwide in July of 2020.

AAKP Board Members and patient members play key roles in top federal initiatives including: the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) Kidney Precision Medicine Project (KPMP); the U.S. Food and Drug Administration (FDA) Patient Engagement Advisory Committee (PEAC), the Kidney Health Initiative (KHI), a partnership between the FDA and the American Society of Nephrology as well as the U.S. Department of Health and Human Services Kidney Innovation Accelerator, or KidneyX.

Established in 1969, AAKP maintains a national and global network of patient advocates, kidney researchers, medical innovation leaders and policy influencers. From 1969-1973, AAKP patients led the effort in the U.S. Congress, alongside senior White House officials, to establish the End Stage Renal Disease Program (ESRD), which has saved over a million lives through modern dialysis coverage as administered by the Centers for Medicare and Medicaid Assistance. For more information, visit www.aakp.org. Follow AAKP on social media: @kidneypatient on Facebook, and @kidneypatients on Twitter.

MEDIA CONTACTS:
Jennifer Duplessie, Marketing
and Communications Manager
jduplessie@aakp.org
(813) 400-2394

Diana Clynes, Executive Director
dclynes@aakp.org
(727) 916-0390

View original content to download multimedia:http://www.prnewswire.com/news-releases/largest-kidney-group-thanks-president-trump-for-signing-pandemic-relief-and-transplant-drug-coverage-301198555.html

SOURCE American Association of Kidney Patients